137 related articles for article (PubMed ID: 30251699)
1. Overexpression of CXCR4 synergizes with LL-37 in the metastasis of breast cancer cells.
Pan WL; Wang Y; Hao Y; Wong JH; Chan WC; Wan DC; Ng TB
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3837-3846. PubMed ID: 30251699
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor RUNX2 up-regulates chemokine receptor CXCR4 to promote invasive and metastatic potentials of human gastric cancer.
Guo ZJ; Yang L; Qian F; Wang YX; Yu X; Ji CD; Cui W; Xiang DF; Zhang X; Zhang P; Wang JM; Cui YH; Bian XW
Oncotarget; 2016 Apr; 7(15):20999-1012. PubMed ID: 27007162
[TBL] [Abstract][Full Text] [Related]
3. A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity.
Ablett MP; O'Brien CS; Sims AH; Farnie G; Clarke RB
Oncotarget; 2014 Feb; 5(3):599-612. PubMed ID: 24583601
[TBL] [Abstract][Full Text] [Related]
4. Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.
Rhodes LV; Antoon JW; Muir SE; Elliott S; Beckman BS; Burow ME
Mol Cancer; 2010 Nov; 9():295. PubMed ID: 21087507
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
Lefort S; Thuleau A; Kieffer Y; Sirven P; Bieche I; Marangoni E; Vincent-Salomon A; Mechta-Grigoriou F
Oncogene; 2017 Mar; 36(9):1211-1222. PubMed ID: 27669438
[TBL] [Abstract][Full Text] [Related]
6. Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer.
Weber G; Chamorro CI; Granath F; Liljegren A; Zreika S; Saidak Z; Sandstedt B; Rotstein S; Mentaverri R; Sánchez F; Pivarcsi A; Ståhle M
Breast Cancer Res; 2009; 11(1):R6. PubMed ID: 19183447
[TBL] [Abstract][Full Text] [Related]
7. CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma.
Zhao BC; Wang ZJ; Mao WZ; Ma HC; Han JG; Zhao B; Xu HM
World J Gastroenterol; 2011 May; 17(19):2389-96. PubMed ID: 21633638
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine.
Mayr C; Neureiter D; Pichler M; Berr F; Wagner A; Kiesslich T; Namberger K
Mol Med Rep; 2015 Aug; 12(2):2247-52. PubMed ID: 25846744
[TBL] [Abstract][Full Text] [Related]
9. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
Zhu WB; Zhao ZF; Zhou X
J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
11. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
[TBL] [Abstract][Full Text] [Related]
12. AGTR1 promotes lymph node metastasis in breast cancer by upregulating CXCR4/SDF-1α and inducing cell migration and invasion.
Ma Y; Xia Z; Ye C; Lu C; Zhou S; Pan J; Liu C; Zhang J; Liu T; Hu T; Xie L; Wu G; Zhao Y
Aging (Albany NY); 2019 Jun; 11(12):3969-3992. PubMed ID: 31219799
[TBL] [Abstract][Full Text] [Related]
13. Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration.
Yuan L; Zhang H; Liu J; Rubin JB; Cho YJ; Shu HK; Schniederjan M; MacDonald TJ
Mol Cancer; 2013 Mar; 12():18. PubMed ID: 23497290
[TBL] [Abstract][Full Text] [Related]
14. VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Pham K; Luo D; Siemann DW; Law BK; Reynolds BA; Hothi P; Foltz G; Harrison JK
Cancer Lett; 2015 Apr; 360(1):60-7. PubMed ID: 25676691
[TBL] [Abstract][Full Text] [Related]
15. Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.
Rhodes LV; Bratton MR; Zhu Y; Tilghman SL; Muir SE; Salvo VA; Tate CR; Elliott S; Nephew KP; Collins-Burow BM; Burow ME
Exp Cell Res; 2011 Nov; 317(18):2573-81. PubMed ID: 21906588
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation.
Zhu Q; Zhang Z; Lu C; Xu F; Mao W; Zhang K; Shou H; Liu Z; Gu J; Ge D
Clin Transl Oncol; 2020 Aug; 22(8):1355-1363. PubMed ID: 31900845
[TBL] [Abstract][Full Text] [Related]
17. CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways.
Sobolik T; Su YJ; Wells S; Ayers GD; Cook RS; Richmond A
Mol Biol Cell; 2014 Mar; 25(5):566-82. PubMed ID: 24403602
[TBL] [Abstract][Full Text] [Related]
18. Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t.
Ward RJ; Pediani JD; Marsango S; Jolly R; Stoneman MR; Biener G; Handel TM; Raicu V; Milligan G
J Biol Chem; 2021; 296():100139. PubMed ID: 33268380
[TBL] [Abstract][Full Text] [Related]
19.
Alzahrani SO; McRobbie G; Khan A; D'huys T; Van Loy T; Walker AN; Renard I; Hubin TJ; Schols D; Burke BP; Archibald SJ
Dalton Trans; 2024 Mar; 53(12):5616-5623. PubMed ID: 38439632
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Yang F; Takagaki Y; Yoshitomi Y; Ikeda T; Li J; Kitada M; Kumagai A; Kawakita E; Shi S; Kanasaki K; Koya D
Cancer Res; 2019 Feb; 79(4):735-746. PubMed ID: 30584072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
